Online inquiry

IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ767MR)

This product GTTS-WQ767MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets LOXL2 gene. The antibody can be applied in Idiopathic pulmonary fibrosis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002318.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4017
UniProt ID Q9Y4K0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ767MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1949MR IVTScrip™ mRNA-Anti-SLITRK6, AGS15C(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AGS15C
GTTS-WQ9900MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA KB-003
GTTS-WQ13750MR IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA REGN 1500
GTTS-WQ2781MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG-282
GTTS-WQ12963MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ3433MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA AV-299
GTTS-WQ7831MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ14282MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RG7155
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW